AHFS March 2022 Update | Pharmaceutical Press

This update contains 4 new monographs, 48 revised monographs, 12 discontinued monographs and 2 new MedWatch alerts.

New monographs: Inclisiran; Levoketoconazole; Ropeginterferon Alfa-2b; Tralokinumab

Revised monographs: Aflibercept; Aminopenicillins General Statement; Amoxicillin; Amoxicillin/Clavulanate; Ampicillin; Ampicillin/Sulbactam; Antihistamines General Statement; Argatroban; Avacopan; Bamlanivimab and Etesevimab; Berotralstat; Bevacizumab; Brolucizumab; Buprenorphine; C1-Esterase Inhibitor (Human); C1-Esterase Inhibitor (Recombinant); Casirivimab and Imdevimab; Clarithromycin; COVID-19 Vaccine (Janssen); COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Diroximel Fumarate; Ecallantide; Eculizumab; Icatibant; Ixazomib Citrate; Lanadelumab-flyo; Ledipasvir and Sofosbuvir; Lemborexant; Lenalidomide; Monomethyl Fumarate; Pegcetacoplan; Pomalidomide; Preface to Penicillins; Ranibizumab; Ravulizumab-cwvz; Remdesivir; Risankizumab-rzaa; Sofosbuvir; Sofosbuvir, Velpatasvir, and Voxilaprevir; Sotorasib; Suvorexant; Thalidomide; Thiazides General Statement; Tildrakizumab-asmn; Umbralisib; Varicella Virus Vaccine Live

Discontinued monographs: Ammonium Chloride; Bendroflumethiazide; Biperiden; chlorpropamide; Diphenido; Edrophonium; Indinavir; Lesinurad; Pegaptanib; Procyclidine; raNITIdine; Tromethamine

New MedWatch alerts on the following monographs: Buprenorphine; Umbralisib